ChiCTR2300068097 版本V1.1 版本创建时间2023/05/13 22:01:13 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300068097 

最近更新日期:

Date of Last Refreshed on:

2023-02-07 11:12:26 

注册时间:

Date of Registration:

2023-02-07 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

苯磺酸瑞马唑仑对声带病损切除术患者术后恢复质量的影响

Public title:

Effects of remimazolam besylate on postoperative recovery quality in patients with vocal cord lesion resection

注册题目简写:

English Acronym:

研究课题的正式科学名称:

苯磺酸瑞马唑仑对声带病损切除术患者术后恢复质量的影响

Scientific title:

Effects of remimazolam besylate on postoperative recovery quality in patients with vocal cord lesion resection

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

焦钟雨 

研究负责人:

王凯 

Applicant:

Zhongyu Jiao 

Study leader:

Kai Wang 

申请注册联系人电话:

Applicant telephone:

15090313121

研究负责人电话:

Study leader's
telephone:

15090313121

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

422018818@qq.com

研究负责人电子邮件:

Study leader's E-mail:

422018818@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

新乡市中心医院

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

河南省新乡市卫滨区新乡市中心医院

研究负责人通讯地址:

河南省新乡市卫滨区防疫站家属院

Applicant address:

Xinxiang Central Hospital, Weibin District, Xinxiang City, Henan Province

Study leader's address:

Henan Province Xinxiang City Weibin District epidemic prevention Station family hospital

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

新乡市中心医院

Applicant's institution:

Xinxiang Central Hospital

研究负责人所在单位:

新乡市中心医院

Affiliation of the Leader:

Xinxiang Central Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2022-553

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

新乡市中心医院伦理委员会

Name of the ethic committee:

Ethics Committee of Xinxiang Central Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2022-12-30 00:00:00

伦理委员会联系人:

贾欢

Contact Name of the ethic committee:

Huan, Jia

伦理委员会联系地址:

河南省新乡市卫滨区金穗大道56号

Contact Address of the ethic committee:

56 Jinsui Dadao, Weibin District, Xinxiang City, Henan Province, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

0373-2041096

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

新乡市中心医院

Primary sponsor:

Xinxiang Central Hospital

研究实施负责(组长)单位地址:

新乡市卫滨区金穗大道56号

Primary sponsor's address:

56 Jinsui Avenue, Weibin District, Xinxiang City

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

河南省

市(区县):

新乡市

Country:

China

Province:

He Nan

City:

Xin Xiang

单位(医院):

新乡市中心医院

具体地址:

河南省新乡市卫滨区金穗大道56号

Institution
hospital:

Xinxiang Central Hospital

Address:

56 Jinsui Dadao, Weibin District, Xinxiang City, Henan Province

经费或物资来源:

新乡医学院研究生科研创新支持计划项目

Source(s) of funding:

Xinxiang Medical College graduate research innovation support program

研究疾病:

声带息肉  

Target disease:

polyp of vocal cord

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

将苯磺酸瑞马唑仑应用于声带息肉切除术中的麻醉诱导与维持与丙泊酚进行对比,于诱导前(T0)、插入气管导管(T1)、手术开始(T2)、手术结束(T3)和拔管(T4)时记录MAP、HR、SpO2、Ramsay评分。记录镇静起效时间、手术时间、苏醒时间、拔管时间和PACU停留时间,记录术中及术后不良反应的发生情况,如低血压、心动过缓、呛咳、体动反应、苏醒期躁动和术后恶心呕吐发生情况等。记录患者术后苏醒质量以及术前、术后1d、术后3d的恢复质量-15量表评分。分析苯磺酸瑞马唑仑应用于声带息肉切除术中的临床效果,观察其有效性、安全性和可行性,为完善临床麻醉方案、提高患者满意度提供相关参考研究。  

Objectives of Study:

The anesthesia induction and maintenance of remazolam besylate in vocal cord polyposectomy were compared with propofol. MAP, HR, SpO2 and Ramsay scores were recorded before induction (T0), insertion of endotracheal tube (T1), start of operation (T2), end of operation (T3) and extubation (T4). The onset time of sedation, operation time, recovery time, extubation time and PACU stay time were recorded, and the occurrence of intraoperative and postoperative adverse reactions, such as hypotension, bradycardia, cough, body movement reaction, recovery agitation, postoperative nausea and vomiting were recorded. The quality of recovery after operation and the quality of recovery -15 scale scores before operation, 1 day and 3 days after operation were recorded. To analyze the clinical effect of remazolam besylate in vocal cord polyposectomy, and to observe its effectiveness, safety and feasibility, so as to provide relevant reference research for improving clinical anesthesia program and improving patient satisfaction.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

①ASA分级为I或II级;②年龄18~60岁、BMI为18~25kg/㎡。③愿意接受试验研究治疗并签署知情同意书。

Inclusion criteria

①ASA grade I or II; ② Age 18 to 60 years old, BMI of 18 to 25kg/㎡. ③ Willing to accept the trial and study treatment and sign the informed consent.

排除标准:

①有严重的心 、脑 、肺 、肝 、肾和代谢疾病病史者。②有酗酒史、安眠药服用史者。 ③术前高血压患者收缩压>180mmHg和(或)舒张压>110mmHg。④有神经肌肉系统疾病 、精神疾病者。⑤怀疑有滥用麻醉性镇痛药或镇静药者。⑥已知对苯二氮卓类药物和阿片类药物过敏者。

Exclusion criteria:

① Patients with a history of severe heart, brain, lung, liver, kidney and metabolic diseases. (2) have a history of alcoholism, sleeping pills. ③ Preoperative systolic blood pressure >180mmHg and/or diastolic blood pressure > 110mmHg in hypertensive patients. ④ People with neuromuscular system diseases and mental diseases. ⑤ Suspected abuse of narcotic analgesics or sedatives. ⑥ People with known allergies to benzodiazepines and opioids.

研究实施时间:

Study execute time:

From 2023-01-10 00:00:00 To 2023-05-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-02-10 00:00:00 To 2023-05-30 00:00:00

干预措施:

Interventions:

组别:

瑞马唑仑组

样本量:

45

Group:

Remazolam group

Sample size:

干预措施:

使用瑞马唑仑进行全麻诱导和维持

干预措施代码:

Intervention:

General anesthesia was induced and maintained with remazolam

Intervention code:

组别:

丙泊酚组

样本量:

45

Group:

Propofol group

Sample size:

干预措施:

使用丙泊酚进行全麻诱导和维持

干预措施代码:

Intervention:

General anesthesia was induced and maintained with propofol

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

河南省 

市(区县):

新乡市 

Country:

China

Province:

Henan province

City:

Xinxiang

单位(医院):

新乡市中心医院 

单位级别:

三甲医院 

Institution
hospital:

Xinxiang Central Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术后恢复质量评分QoR-15

指标类型:

主要指标

Outcome:

Postoperative recovery quality score QoR-15

Type:

Primary indicator

测量时间点:

术前1d、术后1d、3d、5d

测量方法:

问卷调查

Measure time point of outcome:

One day before surgery, one day after surgery, three days after surgery, and five days after surgery

Measure method:

questionnaire survey

指标中文名:

不良反应

指标类型:

次要指标

Outcome:

untoward effect

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

镇静效果

指标类型:

次要指标

Outcome:

Effect of sedation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

对血流动力学影响

指标类型:

主要指标

Outcome:

Effects on hemodynamics

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 60 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

将患者按随机数字表法进行分组,即瑞马唑仑组(R组)和丙泊酚组(P组)。

Randomization Procedure (please state who generates the random number sequence and by what method):

The patients were divided into remazolam group (group R) and propofol group (group P) according to the random number table method by the project leader, Jiao Zhongyu.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

双盲,收集数据者、受试者均不知分组情况。

Blinding:

Double-blind, data collectors and subjects were unaware of the group assignment.

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

根据项目进展,如需要数据资料可与我们团队联系

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

According to the progress of the project, you can contact our team if you need data

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据收集:采用已经设计好的病例报告表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Data collection: the designed case report form was used.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2023-02-07 11:12:01